Clopidogrel,
does it really help with One-year bleeding and net clinical benefit in patients aged 70 or older with NSTE-ACS?
research showsGrade B, 76 points. The co-primary bleeding outcome was 18% with clopidogrel versus 24% with ticagrelor or prasugrel (HR 0.71, 95% CI 0.54-0.94; absolute difference -6 points; P=0.018 for superiority). Net clinical benefit was 28% versus 32% (HR 0.82, 95% CI 0.66-1.03; absolute difference -4 points), meeting the prespecified 2-point noninferiority margin (P=0.03).
ads claimThe potent-antiplatelet benefits in verdicts 1172 and 1321 should not be copied mechanically to patients aged 70 or older at greater bleeding risk. Here clopidogrel was preferable in that older population: the issue is patient selection, not whether a drug is inherently good or bad.
Useful facts when choosing a product
- The co-primary tests were bleeding superiority and net-clinical-benefit noninferiority.
- Bleeding was 6 points lower with clopidogrel.
- Noninferiority does not establish ischemic superiority.
What the research actually shows
Four-gate review: ① Noninferiority design ② listed item ③ net clinical benefit used a "non-inferiority hypothesis, margin of 2%" and passed ④ avoidable with superiority design, so counted. ① Active control only ② listed item ③ both arms received standard P2Y12 inhibition ④ no-antiplatelet placebo care was not ethical, so not counted. ① Unmasked subjective outcome ② listed item ③ open label, but assessors were masked and endpoints were clinical events ④ criterion not met. Both co-primary hypotheses passed.
Why this is classified as B (76)
A 1,002-person ZonMw-funded hard-outcome RCT met both co-primary hypotheses; one noninferiority trial gives B, 76.
Counterpoint. Do not extrapolate directly beyond older NSTE-ACS patients.
Rejudgment record. Source checked — Both co-primary bleeding superiority and net-clinical-benefit noninferiority were met
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | E+ | Meets the clinically important threshold |
The scoring table and the verdict agree (B).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced PLATO major or minor bleeding | B | Rates were 18% versus 24%. |
| Noninferior net clinical benefit | B | Rates were 28% versus 32%, meeting the margin. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Multicenter open-label randomized noninferiority trial with masked outcome assessment | 502 | ZonMw | Superiority for PLATO major or minor bleeding and noninferiority for net clinical benefit | Bleeding 18% vs 24%, HR 0.71 (0.54-0.94), absolute difference -6 points; net clinical benefit 28% vs 32%, HR 0.82 (0.66-1.03), absolute difference -4 points | Direct hard-outcome evidence in older NSTE-ACS |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-26).
Final verification and publication gate: Codex · Verification cutoff: 2026-08-26 · Corrections: none
Cite this verdict
[Chamgap] Benefit of Clopidogrel for 1-Year Bleeding and Ischemic Outcomes in Patients Aged 70 or Older with Non-ST-Elevation Acute Coronary Syndrome — Evidence Grade B·76. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/clopidogrel-older-nste-acs-bleeding-net-clinical-benefit/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.